Memantina Zidrium Teva

Memantine, the active ingredient in Memantina Zidrium, is an NMDA receptor antagonist presented as an oral dosage form for oral use. It is indicated for the treatment of mild to moderate Alzheimer’s disease in adult patients.

GNH USA supplies Memantina Zidrium as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable sourcing for regulated markets. Its global distribution network ensures timely delivery and compliance with local regulatory requirements.

Memantine is used in the management of Alzheimer’s disease, targeting glutamatergic neurotransmission.

- Mild to moderate Alzheimer’s disease: improves cognitive function and daily living activities. - Moderate to severe Alzheimer’s disease: helps maintain functional abilities and may slow disease progression. - Behavioral symptoms of Alzheimer’s disease: may reduce agitation and aggression.

Memantine may be associated with a range of adverse reactions, varying in frequency and severity.

Common Side Effects: - Dizziness - Headache - Constipation - Confusion - Hypertension

Serious or Rare Side Effects: - Seizures - Severe skin reactions (e.g., Stevens‑Johnson syndrome) - Hepatic dysfunction - Suicidal thoughts or behavior

When prescribing memantine, clinicians should consider several safety factors.

- Renal impairment: dose adjustment may be required and renal function should be monitored. - Hepatic impairment: use with caution and monitor liver enzymes. - History of seizures: evaluate risk and monitor for seizure activity. - Elderly patients: observe for increased confusion, dizziness, or falls. - Concomitant NMDA antagonists: avoid combined use to prevent additive neurotoxicity. - Store at ambient temperature: keep in the original packaging, protect from moisture and light.

Memantine can interact with other medicines, requiring attention to avoid adverse outcomes.

Major Interactions (Avoid): - Amantadine: additive NMDA antagonism may increase neurotoxicity. - Ketamine: combined CNS depression and enhanced psychotomimetic effects. - Other NMDA receptor antagonists: risk of excessive inhibition of glutamatergic signaling.

Moderate Interactions (Monitor Closely): - Antihypertensive agents: memantine may potentiate blood pressure lowering. - Central nervous system depressants (e.g., benzodiazepines): may increase dizziness and sedation. - Diuretics: may alter serum electrolytes affecting memantine’s renal clearance.